Immunogenicity of recombinant human bocavirus-1,2 VP2 gene virus-like particles in mice

Immunology

Volumn 142, Issue 1, 2014, Pages 58-66

  Deng, Zhong Hua ^a,b   Hao, Ye Xia ^b   Yao, Li Hong ^b   Xie, Zhi Ping ^b   Gao, Han Chun ^b   Xie, Le Yun ^a   Zhong, Li li ^a   Zhang, Bing ^a   Cao, You De ^a   Duan, Zhao Jun ^b  

^a HUNAN NORMAL UNIVERSITY   (China)

^b National Institute for Viral Disease Control and Prevention   (China)

Author keywords

Human bocavirus; Immunogenicity; Virus like particle; VP2

Indexed keywords

ALUMINUM POTASSIUM SULFATE; BOCAVIRUS 1 VIRUS LIKE PARTICLE VACCINE; BOCAVIRUS 2 VIRUS LIKE PARTICLE VACCINE; GAMMA INTERFERON; IMMUNOGLOBULIN G1 ANTIBODY; IMMUNOGLOBULIN G2A ANTIBODY; UNCLASSIFIED DRUG; VIRUS LIKE PARTICLE VACCINE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIBODY BLOOD LEVEL; ANTIBODY DETECTION; ANTIBODY TITER; ARTICLE; BOCAVIRUS; BOCAVIRUS 1; BOCAVIRUS 2; CELLULAR IMMUNITY; CONTROLLED STUDY; CROSS REACTION; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME LINKED IMMUNOSPOT ASSAY; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOGENICITY; MALE; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; SF9 CELL; SPLEEN CELL; TH1 CELL; TH2 CELL; VIRUS LIKE AGENT;

ADJUVANTS, IMMUNOLOGIC; ALUM COMPOUNDS; ANIMALS; ANTIBODIES, VIRAL; CAPSID PROTEINS; CROSS REACTIONS; ENZYME-LINKED IMMUNOSORBENT ASSAY; ENZYME-LINKED IMMUNOSPOT ASSAY; HUMAN BOCAVIRUS; IMMUNITY, CELLULAR; IMMUNITY, HUMORAL; IMMUNIZATION SCHEDULE; IMMUNOGLOBULIN G; INJECTIONS, INTRADERMAL; INJECTIONS, INTRAMUSCULAR; MALE; MICE; MICE, INBRED BALB C; T-LYMPHOCYTES, HELPER-INDUCER; TIME FACTORS; VIRAL VACCINES; VIRION;

EID: 84897972933     PISSN: 00192805     EISSN: 13652567     Source Type: Journal    
DOI: 10.1111/imm.12202     Document Type: Article

References (41)

1. Allander T, Tammi MT, Eriksson M, Bjerkner A, Tiveljung-Lindell A, Andersson B. Cloning of a human parvovirus by molecular screening of respiratory tract samples. Proc Natl Acad Sci USA 2005; 102:12891-6.
2. Jartti T, Hedman K, Jartti L, Ruuskanen O, Allander T, Soderlund-Venermo M. Human bocavirus - the first 5 years. Rev Med Virol 2011; 22:46-64.
3. Costa C, Bergallo M, Cavallo R. Detection of human bocavirus in bronchoalveolar lavage from Italian adult patients. J Clin Virol 2009; 45:81-2.
4. Garbino J, Soccal PM, Aubert JD et al. Respiratory viruses in bronchoalveolar lavage: a hospital-based cohort study in adults. Thorax 2009; 64:399-404.
5. Wang K, Wang W, Yan H, Ren P, Zhang J, Shen J, Deubel V. Correlation between bocavirus infection and humoral response, and co-infection with other respiratory viruses in children with acute respiratory infection. J Clin Virol 2010; 47:148-55.
6. Hedman L, Soderlund-Venermo M, Jartti T, Ruuskanen O, Hedman K. Dating of human bocavirus infection with protein-denaturing IgG-avidity assays - secondary immune activations are ubiquitous in immunocompetent adults. J Clin Virol 2010; 48:44-8.
7. Windisch W, Schildgen V, Malecki M, Lenz J, Brockmann M, Karagiannidis C, Schildgen O. Detection of HBoV DNA in idiopathic lung fibrosis, Cologne, Germany. J Clin Virol 2013; 58:325-7.
8. Schildgen V, Malecki M, Tillmann RL, Brockmann M, Schildgen O. The human bocavirus is associated with some lung and colorectal cancers and persists in solid tumors. PLoS One 2013; 8:e68020.
9. Chackerian B. Virus-like particles: flexible platforms for vaccine development. Expert Rev Vaccines 2007; 6:381-90.
10. Ludwig C, Wagner R. Virus-like particles - universal molecular toolboxes. Curr Opin Biotechnol 2007; 18:537-45.
11. Roldao A, Mellado MC, Castilho LR, Carrondo MJ, Alves PM. Virus-like particles in vaccine development. Expert Rev Vaccines 2010; 9:1149-76.
12. Paavonen J, Jenkins D, Bosch FX et al. Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial. Lancet 2007; 369:2161-70.
13. Kee GS, Pujar NS, Titchener-Hooker NJ. Study of detergent-mediated liberation of hepatitis B virus-like particles from S. cerevisiae homogenate: identifying a framework for the design of future-generation lipoprotein vaccine processes. Biotechnol Prog 2008; 24:623-31.
14. Inoue M. Protection against uterine cervical cancer by HPV vaccines. Uirusu 2008; 58:155-63.
15. Stanley M, Gissmann L, Nardelli-Haefliger D. Immunobiology of human papillomavirus infection and vaccination - implications for second generation vaccines. Vaccine 2008; 26(Suppl. 10):K62-7.
16. Bernstein DI, El Sahly HM, Keitel WA et al. Safety and immunogenicity of a candidate parvovirus B19 vaccine. Vaccine 2011; 29:7357-63.
17. Kantola K, Hedman L, Allander T, Jartti T, Lehtinen P, Ruuskanen O, Hedman K, Soderlund-Venermo M. Serodiagnosis of human bocavirus infection. Clin Infect Dis 2008; 46:540-6.
18. Lindner J, Karalar L, Zehentmeier S et al. Humoral immune response against human bocavirus VP2 virus-like particles. Viral Immunol 2008; 21:443-9.
19. Kahn JS, Kesebir D, Cotmore SF, D'Abramo A Jr, Cosby C, Weibel C, Tattersall P. Seroepidemiology of human bocavirus defined using recombinant virus-like particles. J Infect Dis 2008; 198:41-50.
20. Kantola K, Hedman L, Arthur J et al. Seroepidemiology of human bocaviruses 1-4. J Infect Dis 2011; 204:1403-12.
21. Lin F, Guan W, Cheng F, Yang N, Pintel D, Qiu J. ELISAs using human bocavirus VP2 virus-like particles for detection of antibodies against HBoV. J Virol Methods 2008; 149:110-7.
22. Zhao LQ, Qian Y, Ding YX, Zhu RN, Deng J, Wang F, Sun Y, Li Y. The expression of the capsid protein VP2 from human bocavirus identified in Beijing and the formation of virus-like particles (VLPs) in insect cells. Bing Du Xue Bao 2009; 25:333-8.
23. Rammensee H, Bachmann J, Emmerich NP, Bachor OA, Stevanovic S. SYFPEITHI: database for MHC ligands and peptide motifs. Immunogenetics 1999; 50:213-9.
24. Lundegaard C, Lamberth K, Harndahl M, Buus S, Lund O, Nielsen M. NetMHC-3.0: accurate web accessible predictions of human, mouse and monkey MHC class I affinities for peptides of length 8-11. Nucleic Acids Res 2008; 36(Web Server issue):W509-12.
25. Wilson KM, Di Camillo C, Doughty L, Dax EM. Humoral immune response to primary rubella virus infection. Clin Vaccine Immunol 2006; 13:380-6.
26. Nedeljkovic J, Jovanovic T, Oker-Blom C. Maturation of IgG avidity to individual rubella virus structural proteins. J Clin Virol 2001; 22:47-54.
27. Gurda BL, Parent KN, Bladek H et al. Human bocavirus capsid structure: insights into the structural repertoire of the parvoviridae. J Virol 2010; 84:5880-9.
28. Brieu N, Gay B, Segondy M, Foulongne V. Electron microscopy observation of human bocavirus (HBoV) in nasopharyngeal samples from HBoV-infected children. J Clin Microbiol 2007; 45:3419-20.
29. Tamminen K, Huhti L, Koho T, Lappalainen S, Hytonen VP, Vesikari T, Blazevic V. A comparison of immunogenicity of norovirus GII-4 virus-like particles and P-particles. Immunology 2011; 135:89-99.
30. Buonaguro L, Tornesello ML, Buonaguro FM. Virus-like particles as particulate vaccines. Curr HIV Res 2010; 8:299-309.
31. Zhang LF, Zhou J, Chen S et al. HPV6b virus like particles are potent immunogens without adjuvant in man. Vaccine 2000; 18:1051-8.
32. McKee AS, Munks MW, MacLeod MK, Fleenor CJ, Van Rooijen N, Kappler JW, Marrack P. Alum induces innate immune responses through macrophage and mast cell sensors, but these sensors are not required for alum to act as an adjuvant for specific immunity. J Immunol 2009; 183:4403-14.
33. Calabro S, Tortoli M, Baudner BC et al. Vaccine adjuvants alum and MF59 induce rapid recruitment of neutrophils and monocytes that participate in antigen transport to draining lymph nodes. Vaccine 2011; 29:1812-23.
34. Lambrecht BN, Kool M, Willart MA, Hammad H. Mechanism of action of clinically approved adjuvants. Curr Opin Immunol 2009; 21:23-9.
35. Crisci E, Fraile L, Moreno N et al. Chimeric calicivirus-like particles elicit specific immune responses in pigs. Vaccine 2012; 30:2427-39.
36. Kemp TJ, Hildesheim A, Safaeian M et al. HPV16/18 L1 VLP vaccine induces cross-neutralizing antibodies that may mediate cross-protection. Vaccine 2011; 29:2011-4.
37. Fiejka M, Aleksandrowicz J. Aluminum as an adjuvant in vaccines and post-vaccine reactions. Rocz Panstw Zakl Hig 1993; 44:73-80.
38. Kool M, Fierens K, Lambrecht BN. Alum adjuvant: some of the tricks of the oldest adjuvant. J Med Microbiol 2012; 61(Pt 7):927-34.
39. Ormstad H, Groeng EC, Duffort O, Lovik M. The effect of endotoxin on the production of IgE, IgG1 and IgG2a antibodies against the cat allergen Fel d 1 in mice. Toxicology 2003; 188:309-18.
40. Hollo K, Glant TT, Garzo M, Finnegan A, Mikecz K, Buzas E. Complex pattern of Th1 and Th2 activation with a preferential increase of autoreactive Th1 cells in BALB/c mice with proteoglycan (aggrecan)-induced arthritis. Clin Exp Immunol 2000; 120:167-73.
41. Huang Q, Deng X, Yan Z et al. Establishment of a reverse genetics system for studying human bocavirus in human airway epithelia. PLoS Pathog 2012; 8:e1002899.